Trial Profile
Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary) ; Abiraterone; Prednisone
- Indications Bone metastases
- Focus Therapeutic Use
- Acronyms eRADicAte
- 10 May 2016 Results presented at the 111th Annual Meeting of the American Urological Association
- 11 Jan 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 04 Jan 2016 Results will be presented at the 2016 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU), according to a Bayer media release.